notre dernier livreDécouvrez notre dernier livre « Somatostatin analogues : From research to clinical practice », disponible ici
publications dans des journaux avec facteur d'impact
Filtres :
Predictors of overall and disease free survival in metastatic castration resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. Sathekge M, Bruchertseifer F, Vorster M, Lawal I, Knoesen O, Mahapane J, Davis C, Reyneke F, Maes A, Kratochwil C, Lengana T, Giesel F, Van de Wiele C, Morgenstern A.J Nucl Med 2020;61(1):62-69PSMA expression on tumor neovasculature of solid tumors. Van de Wiele C, Sathekge M, de Spiegeleer B, de Jonghe P, Debriyne P, Borms M, Beels L, Maes A.Histol Histopathol 2020; in pressPSMA-targeting Positron Emission Emission Agents for imaging solid tumors other than non-prostate carcinoma: a systematic review Van de Wiele C, Sathekge M, De Spiegleer B, de Jonghe P, Beels L, Maes AInt J Mol Sci 2019;20(19).pii:E4886.doi:10.3390/ijms20194886FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection Lawal I, Ololade K, Popoola G, ANkrah A, Vorster M, Maes A, Mogkoro N, Van de Wiele C, Sathekge MQ J Nucl Med Mol Imaging 2019.may 8. doi:10.23736/S1824-4785.19.03156-X68Ga-citrate PET/CT in tuberculosis: a pilot study. Vorste M, Maes A, Van de Wiele C, Sathekge M.Q J Nucl Med Mol Imaging 2019; 63(1):48-55Reversible myocardial perfusion defects in patients not suffering from obstructive epicardial coronary artery disease as assessed by coronary angiography: a review of the literature. Van de Wiele C, Rimbu A, Belhocine T, De Spiegeleer B, Sathekge M, Maes A.Q J Nucl Med Mol Imaging, 2018; 62: 6369-6383.68Ga-PSMA-11 PET/CT in primary staging of prostate carcinoma: preliminary results on the differences between black and white South-Africans. Sathekge M, Lengana T, Maes A, Vorster M, Zeevaart J, Lawala I, Ebenhan T, Van de Wiele C.Eur J Nucl Med Mol Imaging 2018; 45: 226-23468Ga-PSMA-HBED-CC PET/CT imaging in black versus white South-African patients with prostate carcinoma presenting with a low volume androgen-dependent biochemical recurrence: a prospective study. Lengana T, Van de Wiele C, Lawal I, Maes A, Ebehna T, Boshomonae T, Zeevaart J, ANkrah A, Mokgoro N, Vorster M, Sathekge M.Nucl Med Commun 2018; 39: 179-185Screening of quorum sensing peptides for biological effects in neuronal cells. Janssens Y, Wynendaele E, Verbeke F, Debunne N, Gevaert B, Audenaert K, Van de Wiele C, De Spiegeleer B.Peptides 2018; 101: 150-156.Patient-specific lean-body mass can be estimated from limited-coverage computed tomography images. Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H.Nucl Med Commun 2018; 39: 521-526.Blood-brain barrier transport kinetics of NOTA-modified proteins: the somatotropin case. Bracke N, Janssens Y, Wynendaele E, Tack L, Maes A, Van de Wiele C, Sathekge M, De Spiegeleer B.Q J Nucl Med Mol Imaging 2018; doi: 10.23736/S1824-4785.18.03025-X.68Ga-PSMA PET/CT repalicng bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli? Lengana T, Lawal I, Boshomane T, Popoola G, MOKOala K, Moshokoa E, Maes A, Mokgoror N, Van de Wiele C, Vorster M, Sathekge M. Clin Genitourin Cancer 2018; 16: 392-401.Tuberculosis.ANkrah A, Glaudemans A, Maes A, Van de Wiele C, Dierckx R, Vorster M, Sathekge M.Semin Nucl Med 2018; 48: 108-130.Prognostic value of pre-treatment F-18 FDG PET metabolic metrics in patients with locally advanced carcinoma of the anus with and without HIV infection. Lawala I, Ankrah A, Mokoala K, Popoola G, Kaoma C, Maes A, Mokgoro N, Van de Wiele C, Sathekge M.Nuklearmedizin 2018; 57: 190-197.Impact of PET reconstruction protocols on quantification of lesions that fulfill the PERCIST criteria Devriese J, Beels L, Maes A, Van de Wiele C, Pottel HEJNNMI PHys 2018; 7;(5)1: 35:10.1186/s40658-018-0235-6Stable metabolic disease on FDG-PET provides information on response to endocrine therapy for breast cancer Kruse V, Van de Wiele C, Maes A, Borms M, Van Belle S, Coquyt VQ J Nucl Med Mol Imaging, 2017; 61: 108-11468Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, Ebenhan T, Van de Wiele CEur J Nucl Med Mol Imaging 2017, 44: 689-694.Metabolic and morphological measurements of subcutaneous and visceral fat and their relationship with disease stage and overall survival in newly diagnosed pancreatic adenocarcinoma. Van de Wiele C, Van Vlaenderen M, D'Huklst L, Delcourt A, Copin D, De Spiegeleer B, Maes A.Eur J Nucl Med Mol Imaging 2017; 44: 110-116.In vitro functional quality characterization of NOTA-modified somatropins. Bracke N, Han Y, Wynendaele E, Verbeke F, Xu X, Gevaert B, Maes A, Van de Wiele C, Sathekge M, De Saeger S, De Spiegeleer BAnalytical Chemistry 2017, 89: 2764-2772.Peptides as quorum sensing molecules: measurement techniques and obtained levels in vitro and in vivo. Verbeke F, De Craemer S, Debunne N, Janssens Y, Wynendaele E, Van de Wiele C, De Spiegeleer B.Front Neurosci 2017; 12: 183.doi:10.3389/fnins.2017.00183The role of F-18 FDG PET/CT in evaluating the impact of HIV infection on tumour burden and therapy outcome in patients with Hodgkin Lymphoma. Lawal I, Nozipo E, Nyalame M, Lerwine H, Modiselle M, Ankrah A, Msomi A, Mokgor N, Boshomane T, Van de Wiele C, Sathekge M.Eur J Nucl Med Mol Imaging 2017; 44: 2025-2033.FDG PET/CT findings in multifocal splenic lymphoma. Van de Wiele C, Verstreate K, Bourgeois S, Maes A.Hell J Nucl Med 2017, 20: 182-183.Gallium-68 PET: a powerful generator-based alternative to infection and inflammation imaging Vorster M, Maes A, Van de Wiele C, Sathekge MSemin Nucl Med 2016; 46: 436-44718F-FDG PET/CT imaging for the assessment of the volume of the spleen Smeets P, Mees G, Ham H, Maes A, Verstraete K, Van de Wiele CQ J Nucl Med Mol Imaging, 2016; 60: 48-53.False positive axilary lymph nodes due to silicone adenitis on (18)F-FDG PET/CT in an oncological setting. D’Hulst L, Nicolaij D, Beels L, Gheysens O, Alaerts H, Van de Wiele C, Maes A.J Thorac Oncol 2016; 11(6):e73-75. Doi:10.1016/j.jtho.2016.01.001.Preclinical validation of automated dual-energy X-ray absorptiometry and computed tomography-based body composition measurements. Devriese J, Beels L, Van de Wiele C, Maes A, Gheysens O, Pottel H.Q J Nucl Med Mol Imaging 2016; 60: 40-47.Review of clinically accessible methods to determine lean body mass for normalization of standardized uptake values. Devriese J, Beels L, Maes A, Van de Wiele C, Gheysens O, Pottel H.Q J Nucl Med Mol Imaging 2016; 60: 1-11.Accuracy of bone SPECT/CT for identifying hardware loosening in patients that underwent lumbar fusion with pedicle screws. Hudyana H, Maes A, Vandenberghe T, Fidlers L, Sathekge M, Nicolai D, Van de Wiele C.Eur J Nucl Med Mol Imaging, 2016; 43: 349-354.Evaluation of CT-based SUV normalization Devriese J, Beels L, Maes A, Van de Wiele C, Pottel H.PMB, 2016, 61: 6369-6383.The quorum sensing peptides PrG, CSP and EDF promote angiogenesis and invasion of breast cancer cells in vitro Wynendaele E, Verbeke F, D’Hondt M, Hendrix A, Van de Wiele C, Burvenich C, Peremans K, De Wever O, Bracke M, De Spiegeleer BPLoS One 2015;10(3):e0119471.doi:10/1371/journal.pone.0119471.Quorum sensing peptides selectively penetrate the blood brain-barrier Wynendaele E, Verbeke F, Stalmans S, Gevaert B, Janssens Y, Van de Wiele C, Peremans K, Burvenich C, De Spiegeleer B.PLoS One, 2015; 10(11):e142071.doi:10.1371/journal.pone.014271.99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Belhocine T, Blankenberg F, Karchova M, Stitt L, Vanderheyden JL, Hoeben F, Van de Wiele C.Eur J Nucl Med Mol Imaging, 2015, 42: 2083-2097.Reproducibility of intratumoral FDG distribution and of metabolic tumor volume in 18F-FDG PET Kruse V, Mees G, D’Asseler Y, Maes A, Borms M, Cocquyt V, Van de Wiele CQ J Nucl Med Mol Imaging 2015; 59: 462-468PET/CT imaging of Tuberculosis with 68Ga-citrate. M Vorster, A Maes, C Van de Wiele, M SathekgeMol Imaging Radionucl Ther 2015; 24: 42. Doi: 10.4274/mirt.24.01.09Reproducibility of FDG PET based metabolic tumor volume measurements and their FDG distribution within Kruse V, Mees G, D’Asseler Y, Maes A, Borms M, Cocquyt V, Van de Wiele CQ J Nucl Med Mol Imaging 2015; 59: 462-468.PET AND SPECT imaging of Monocyte and Macrophage trafficking Van de Wiele C, Sathekge M, Maes A.Q J Nucl Med Mol Imaging, 2014, 58: 269-275.Effect of AIDS on women who have sex-determined issues Sathekge M, Maes A, Van de Wiele C, Dadachova E.Seminars in Nuclear medicine, 2014, 44: 489-498.CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence: factors influencing the area under the ROC-curve Kruse V, Van de Wiele C, Maes A, Borms M, Pottel H, van Belle S, Coquyt VNuklearmedizin 2014, 53: 131-138.Analytical characterization of NOTA-modified somatropins Bracke N, Wynendaele E, DHondt M, Haselberg R, Pauwels E, Van de Wiele C, De Spiegeleer BJ Pharm Biomed Analysis, 2014; 96; 1-9.Effect of AIDS on women who have sex-determined issues Sathekge M, Maes A, Van de Wiele C, Dadachova E.Seminars in Nuclear medicine, 2014, 44: 489-498.Evaluating the possible role of 68Ga-citrate PET/CT in the characterization of indeterminate lung lesions Vorster M, Maes A, Jacobs A, Malefahlo S, Pottel H, Van de Wiele C, Sathekge M.Ann Nucl Med 2014; 28: 523-530.68Ga-citrate PET/CT in tuberculosis: a pilot study Vorster M, Maes A, Van de Wiele C, Sathekge M.Q J Nucl Med Mol Imaging 2014, epub ahead of print.Nuclear medicine imaging for personalized medicine (editorial) C Van de Wiele, G MeesCurr Pharm Des, 2014; 20: 2231-2233.Radiolabeled probes targeting tumor hypoxia for personalized medicine G Mees, A Maes, M Sathekge, C Van de WieleCurr Pharm Des, 2014, 20: 2308-2318.Personalized medicine in oncology, the potential role of nuclear medicine imaging C Van de Wiele, G MeesCurr Pharm Des, 2014; 20: 2231-2233Pretreatment quantitative 99mTc-MAA SPECT/CT and FDG PET/CT VOI analysis of liver metastases: relationship with treatment response to SIRT C Van de Wiele, K Stellamans, E Brugman, G Mees, B De Spiegeleer, Y D’Asseler, A MaesNuklearmedizin, 2013, 52: 21-27.Pharmacological activation of tumor hypoxia: a means to increase tumor FDG uptake? G Mees, R Dierckx, C Vangestel, D Laukens, N Van Damme, C Van de WieleMol Imaging 2013, 12: 49-58.SAM in FDG PET assessment of treatment response in colorectal liver metastases J Mertens, S Debruyne, N Van Damme, P Smeets, W Ceelen, R Troisi, S Laurent, K Geboes, M Peeters, I Goethals, C Van de WieleEur J Nucl Med Mol Imaging, 2013, 40:1214-1222.Quorumpeps database: chemical space and functionality of quorum-sensing peptides E Wynendaele, A Bronselaar, J Nielandt, M D’Hondt, S Stalmans, N Bracke, C Van de Wiele, G De Tré, B De SpiegeleerNARS, 2013, 41: D655-659.Serum tumor markers and PET-CT imaging for tumor recurrence detection V Kruse, V Cocquyt, M Borms, A Maes, C Van de WieleAnn Nucl Med, 2013, 27:97-104.FDG PET/CT in HIV and TB M Sathekge, A Maes, C Van de WieleSem Nucl Med 2013, 43: 349-366.Ga-68: a systematic review of its non-oncological applications Vorster M, Maes A, Van de Wiele C, Sathekge MNucl Med Commun: 2013; 34: 834-854.Predictive and prognostic value of metabolic tumor volume and total lesion glycolysis in solid tumors C Van de Wiele, V Kruse, P Smeets, M Sathekge, A MaesEur J Nucl Med Mol Imaging, 2013; 40: 290-301.Probes for non-invasive matrix metalloproteinase-targeted imaging with PET and SPECT. Matusiak N, van Waarde A, Bischoff R, Oltenfreiter R, van de Wiele C, Dierckx RA, Elsinga PH.Curr Pharm Des 2013, 19: 4647-4675.Three-phase adaptive dose-painting-by-numbers for head and neck cancer: initial results of the phase I clinical trial. Berwouts D, Olteanu L, Duprez F, Vercauteren T, De Gersem W, De Neve W, Van de Wiele C, Madani I.RadiotherOncol 2013; 107: 310-316.Human biodistribution and dosimetry of 195mPt-cisplatin M Sathekge, J Wagenerer, N Soni, B Marjanovic-Painter, C Zinn, C Van de Wiele, Y D’ASseler, G Perkins, S Smith, J ZeevaartNuklearmedizin 2013, 52: 222-227.Nuclear medicine imaging in tuberculosis using commercially available radiopharmaceuticals M Sathekge, A Maes, M Vorster, Y D’Asseler, C Van de WieleNucl Med Communications, 2012, 33: 581-590.Tuberculous lymphadenitis: FDG PET and CT findings in responsive and non-responsive disease M Sathekge, A Maes, Y ‘Asseler, M Kgomo, C Van de WieleEur J Nucl Med, 2012, 39: 1184-1190.Reply: 18F-FDG PET/CT as a sensitive and early treatment monitoring tool: will this become the major thrust for its clinical application in infectious and inflammatory conditions. M Sathekge, A Maes, C Van de WieleJ Nucl Med, 2012;53: 165-166.SIRT of liver metastases: physiological and pathophysiological considerations C Van de Wiele, A Maes, E Brugman, Y D’Asseler, B De Spiegeleer, G Mees, K StellamansEur J Nucl Med Mol Imaging, 2012; 10: 1646-1655.Tumor perfusion using first pass FDG PET images J Mertens, H Ham, A DeZutter, A Depicker, C Van de Wiele, Smeets P, Goethals IClin Nucl Med 2012; 37: 166-167.Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases S De Bruyne, N VanDamme, K Geboes, W Ceelen, P Smeets, S Laurent, L Ferdinande, J Mertens, C Van de Wiele, R Troisi, M PeetersBr J Cancer, 2012; 106: 1926-1933.Standardized added metabolic activity (SAM), a partial volume independent marker of total lesion glycolysis J Mertens, A Dobbeleir, H Ham, Y D’Asseler, I Goethals, C Van de WieleEur J Nucl Med, 2012; 39: 1441-1448.In vitro 18F-FDG uptake: practical considerations K Mertens, G Mees, B Lambert, C Van de Wiele, I GoethalsCancer Biother Radiopharm, 2012; 27: 183-188.99mTc-tricarbonyl-His-CNA35 as an imaging agent for the detection of tumor vasculature G Mees, R Dierckx, K Mertens, S Vermeire, M Vansteenkiste, C Reutelingsperger, Y D’Asseler, K Peremans, N Van Damme, C Van de WieleJ Nucl Med 2012, 53: 464-471.In vitro metabolic stability of iodinated obestatin peptide B De Spiegeleer, S Vandorpe, V Vergote, E Pauwels, C Van de Wiele, JC Saint-Solis, P Garcia-SolisJ Biochemistry, 2012; 33: 272-278.Brainpeps: the blood-brain barrier peptide database S Vandorpe, A Ronselaer, S Stalmans, K Audenaert, C Van de Wiele, C Burvenich, K Peremans, H Hsuchou, G De Tre, B De SpiegeleerBrain Struct Funct Journal, 2012; 217: 687-718.The potential role of quorum-sensing peptides in oncology E Wynendaele, E Pauwels, C Van de Wiele, C Burvenich, B De SpiegeleerMedical Hypotheses, 2012, 78: 814-817.SPECT imaging of the early time course of therapy-induced cell death using 99mTc-(CO)3 His-annexin A5 in a colorectal cancer xenograft model C Vangestel, C Van de Wiele, G Mees, S Staelens, C Reutelingsperger, P Pauwels, N Van Damme, M PeetersMol Imaging, 2012, 11: 135-147.Multimerization improves targeting of peptide radio-pharmaceuticals G Carlucci, H Ananias, Z Yu, C Van de Wiele, R Dierckx, I de Jong, Ph ElsingaCurr Pharm Des, 2012, 18: 2501-2516.Use of FDG PET to predict response to first line tuberculostatics in HIV-associated tuberculosis M Sathekge, A Maes, M Kgomo, A Stolz, C Van de WieleJ Nucl Med, 2011, 52: 880-885.In vivo imaging of apoptosis : an update C Vangestel, G Mees, R Oltenfreiter, H Boersma, Ph Elsinga, C Reutelingsperger, B De Spiegeleer, M Peeters, C Van de WieleMol Imaging, 2011; 10: 340-358.Expression and prognostic value of glucose transporters and hexokinases in tonsil and mobile tongue squamous cell carcinoma Ph Deron, H Vermeersch, G Mees, V Vangestel, P pauwels, C Van de WieleHistology and Histopathology, 2011; 26: 1165-1172.FDG uptake in primary squamous cell carcinoma of the head and neck. The relationship between overexpression of glucose transporters and hexokinases, tumor proliferation and apoptosis. Ph Deron, C Vangestel, I Goethals, A De Potter, M Peeters, H Vermeersch, C Van de WieleNuklearmedizin, 2011; 50: 15-21.Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography. Ph Deron, K Bonte, H Vermeersch, C Van de WieleCancer Biother Radiopharm 2011; 26: 331-334.Metabolic correlates of tumour hypoxia in a spontaneous canine mammary gland tumour G Mees, C Vangestel, R Dierckx, S Loomans, N Van Damme, Peremans K, H De Rooster, B Van Goetham, P Pauwels, R Ducatel, C Van de WieleResearch in Veterinary Oncology, 2011; 91: e125-128.Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck Ph Deron, K Mertens, I Goethals, S Rottey, W De Neve, H Vermeersch, C Van de WieleNuklearmedizin, 2011; 50: 141-146.Quantitative perfusion scintigraphy or anatomic segment method for estimating pospoperative pulmonary function in resected lung cancer patients: a retrospective analysis T Holvoet, J Van Meerbeeck, C Van de Wiele, B Salhi, E DeromLung Cancer, 2011, 74: 212-21899mTc-HYNIC(tricine/TPPTS)-Aca-Bombesin(7-14), a targeted imaging agent with microspect in a PC-3 prostate cancer xenograft model. H Ananias, Z Yu, RA Dierckx, C Van de Wiele, W Helfrich, F Wang, Y Yan, X Chen, I De Jong, Ph ElsingaMol Pharm 2011, 8: 1165-1173.Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. I Madani, F Duprez, T Boterberg, C Van de Wiele, K Bonte, P Deron, W dGersem, M Coghe, De Neve WRadiother Oncol 2011, 101: 351-355.99mTc-(CO)3 His-Annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab. C Vangestel, C Van de Wiele, N Van Damme, S Staelens, P Pauwels, C Reutelingsperger, M PeetersJ Nucl Med 2011, 52: 1786-1794.FDG uptake by lymph nodes of HIV patients is inversely related to CD4 cell count M Sathekge, A Maes, M Kgomo, C Van de WieleNucl Med Commun, 2010, 31: 137-140.Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy M Sathekge, A Maes, M Kgomo, A Stolz, A Alfred, C Van de WieleNucl Med Commun, 2010, Feb, 31: 311-314.Impact of FDG PET imaging on the management of TBC treatment: a pilot study M Sathekge, A Maes, M Kgomo, A Stolz, H Pottel, C Van de WieleNuklearmedizin 2010;49: 35-40.Dual time point PET/CT for differentiating benign from malignant solitary pulmonary nodules: a prospective study M Sathekge, A Maes, M Kgomo, H Pottel, C Van de WieleS Afr J Med, 2010, 100; 598-601.Scapular osteomyelitis as a rare complication of staphylococcus aureus endocarditis: bone scintigraphy findings J Mertens, V Van Gaever, H Ham, C Van de WieleClin Nucl Med 2010, 35: 595-597.FDG uptake in lymph nodes of HIV+ and tuberculosis patients: implications for cancer staging M Sathekge, A Maes, M Kgomo, H Pottel, A Stolz, C Van de WieleQuart J Nucl Med, 2010, 54: 698-703.Radioembolization in hepatocellular carcinoma C Van de WieleCDDP, 2010; 7: 247-252.FDG PET in children: do we have enough counts A Dobbeleir, H Ham, I Goethals, Y D’Asseler, C Van de WieleNucl Med Commun, 2010; 31: 191-194.CA-IX expression correlates with FDG uptake by primary NSCLC G Mees, C Van Gestel, R Dierckx, P Pauwels, J Van Meerbeeck, C Van de WieleCancer Biother Radiopharm, 2010; 25: 149-154.A simple test to determine the quality of your clinical PET images A Dobbeleir, H Ham, I Goethalsd, J Keppens, Y D’Asseler, C Van de WieleAnn Nucl Med 2010; 24: 751-777Membrane type 1 Matrix Metalloproteinase detection in tumors, using the iodinated endogenous [123I]-Tissue inhibitor 2 of metalloproteinases as imaging agent M Van Steenkiste, C Van de Wiele, F De VosCancer Biotherapy and Radiopharmaceuticals, 2010, 25: 511-520Measurement of porto-systemic shunting in mice by novel three-dimensional micro-single photon emission computed tomography imaging enabling longitudinal follow-up C Van Steenkiste, S Staelens, C Deleye, F De Vos, S Vandenberghe, A Geerts, C Van de Wiele, M De Vos, H Van Vlierverghe, I ColleLiver Int, 2010, 30: 1211-1220In vitro and in vivo evaluation of 99mTc-labeled tricarbonyl His- annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells C Vangestel, M Peeters, R Oltenfreiter, S Staelens, Y D’Asseler, M Van Steenkiste, J Philippé , D Kusters, C Reutelingsperger, N Van Damme , C Van de WieleJ Nucl Med Biol, 2010, 37: 965-975Positron emission tomography in patients suffering from HIV M Sathekge, A Maes, C Van de WieleEur J Nucl Med, 2009; 36: 1176-1184.RIT of NHL: the next step A Otte, C Van de Wiele, R DierckxNuc Med Commun 2009; 30: 5-15.Radiolabelled resin microspheres for the treatment of primary and secondary malignant liver tumors
C. Van de Wiele, L. Defreyne, A. Maes, M. Peeters, B. LambertQuart J Nucl Med 2009; 53: 317-324.FDG-PET for monitoring response to local and locoregional therapy in HCC and livermetastases R. Dierckx, A. Maes, M Peeters, C. Van de WieleQuart J Nucl Med 2009; 53: 336-342.Selective internal radionuclide therapy of HCC and livermetastases: a locoregional or worldwide therapy? C. Van de WieleQuart J Nucl Med 2009; 53: 302-304.Expression of hexokinases and glucose transporters in treated and untreated esophageal adenocarcinoma P Phonteyne, P Pauwels, V Casneuf, N Vandamme, M Peeters, R Dierckx, C Van de WieleHistology and histopathology, 2009; 24: 971-977.Molecular imaging of hypoxia with radiolabeled agents G Mees, C Vangestel, R Dierckx, C Van de WieleEur J Nucl Med Molecular Imaging, 2009; 36: 1674-1686.Combined effect of EPO and radiotherapy on the expression of endogenous markers of tumor metabolism and metastasis G Mees, Ph Phonteyne, W Ceelen, T Boterberg, P Pauwels, C Vangestel, N Vandamme, M Peeters, R Dierckx, C Van de WieleCancer Biother Radiopharm, 2009; 24: 565-572.Influence of chemotherapy on the biodistribution of 99mTc-HYNIC Annexin V in humans S Rottey, B Van den Bossche, G Slegers, S Van Belle, C Van de WieleQuart J Nucl Med, 2009, 53: 127-132The immune system and cancer D Loose, C Van de WieleCancer Biother and Radiopharm, 2009, 24: 369-376Gallium citrate scintigraphy to assess metastatic spread in a dog with an oral melanoma T Liuti , J de Vos , T Bosman , C Van de Wiele , G Grinwis, H van Bree, K PeremansJ Small Anim Pract. 2009, 50: 31-34Forcing cancer cells to commit suicide C Van Gestel, C Van de Wiele, G Mees, M PeetersCancer Biother Radiopharm, 2009, 24: 395-407Glomerular filtration rate is a confounder for the determination of soluble mesothelin in serum Hollevoet K, Bernard D, De Geeter F, Walgraeve N, Van den Eeckhaut A, Vanholder R, Van de Wiele C, Stove V, van Meerbeeck J, Delanghe JClinical Chemistry, 2009, 55: 1431-1433Development of peptide receptor binding assays: methods to avoid false negatives V Vergote, S Van Dorpe, M Verbeken, C Burvenich, C Van de Wiele, W Banks, B De SpiegeleerEur J Nucl Med, 2009, 158: 97-102Quality specifications for peptide drugs: a regulatory-pharmaceutical approach V Vergote, C Burvenich, C Van de Wiele , B De SpiegeleerJ Peptide Science, 2009, 15: 697-710Post-stress left ventricular ejection fraction is an independent predictor of major cardiac events in patients with coronary artery disease and impaired left ventricular function O De Winter, N Van de Veire, P De Bondt, C Van de Wiele, M De Buyzere, G De Backer, T Gillebert, R Dierckx, J De SutterQuarterly J Nucl Med, 2008: 52: 296-304.Growth factor/ peptide receptor imaging for the development of targeted therapy in oncology C Van de Wiele, Boersma H, Dierckx R, De Spiegeleer B, Elsinga PhCurrent Pharmaceutical Design, 2008; 14: 3340-3347.FDG uptake by the bone marrow in NSCLC patients is related to TGF- but not to VEGF or G-CSF C Van de Wiele, F VandeVyver, C Debruyne, J Philippé, J van MeerbeeckEur J Nucl Med, 2008; 35: 519-522.FDG PET, a marker of hypoxia? RA. Dierckx, C Van de WieleEur J Nucl Med, 2008; 35: 1544-1549.Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. V Casneuf, Ph Fonteyne, N Van Damme, P Demetter, P Pauwels, B de Hemptinne, M De Vos, C Van de Wiele, M PeetersCancer Investigations, 2008; 26: 852-859.FDG uptake of the primary tumor in untreated primary squamos cell carcinoma of the head and neck is related to WBC count and to FDG uptake by the bone marrow F Cicone, Ph Deron, H Vermeersch, A Signore, F Scopinaro, C Van de WieleNucl Med Commun, 2008; 29: 431-435.123I-Interleukin-2 uptake in squamous cell carcinoma of the head and neck D Loose, A Signore, L Staelens, K Vanden Bulcke, H Vermeersch, R Dierckx, E Bonanno, C Van de WieleEur J Nucl Med, 2008; 35: 281-286Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous cell carcinoma of the head and neck D Loose, A Signore, E Bonanno, H Vermeersch, R Dierckx, Ph Deron, C Van de WieleCancer Biother Radiopharm, 2008, 23: 25-33.Gastrin releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry C Van de Wiele, Ph Phonteyne, P Pauwels, R Vandenbroecke, V Cocquyt, R DierckxJ Nucl Med, 2008, 49: 260-264.Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals Ananias H, de Jong I, Dierckx R, Van de Wiele C, Elsinga PhCurrent Pharmaceutical Design, 2008, 14; 3033-3047Radiolabelled chemotherapeutics S Rottey, A Signore, C Van de WieleQuart J Nucl Med, 2007; 51: 139-151.Differences of cortical 5-HT2a receptor binding with SPECT in subtypes of anorexia nervosa I Goethals, M Vervaet, K Audenaert, F Jacobs, C Van de Wiele, H ham, RA Diercxk, C Van HeeringenJ Psychiatr Res, 2007; 41: 455-458IL-2 imaging in patients suffering from metastatic renal cell carcinoma V Renard, L Staelens, A Signore, S Van Belle, R Diercxk, C Van de WieleQuart J Nucl Med, 2007; 51: 352-35699mTc-HYNIC Annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy S Rottey, Loose D, Vakaet L, Lahorte C, Vermeersch H, Van Belle S, Van de Wiele CQuarterly J Nucl Med, 2007, 51: 182-188Fasting blood glucose levels are related to exercise capacity in coronary artery disease patients Van de Veire N, De Winter O, Giri M, De Buyzere M, Van de Wiele C, De Sutter JAm Heart J, 2006, 152: 486-492.123I-labelled Interleukin-12, a new radiopharmaceutical for imaging th-1 mediated chronic inflammation: in vitro and animal studies A Annovazzi, B Cornelissen, G Slegers, C D’Alessandria, E Bonanno, C Van de Wiele, F Scopinaro, A SignoreCancer Biother Radiopharm 2006; 33: 474-482.188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: an activity escalation study B Lambert, K Bacher, L Defreyne, H Van Vlierberghe, JM Jeong, RF Wang, JP Van Meerbeeck, P Smeets, R Troisi, H Thierens, F De Vos, C Van deWieleEur J Nucl Med, 2006; 33: 344-352.Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for HCC B Lambert, L De Ridder, F De Vos, G Slegers, V De Gelder, C Van de Wiele, H ThierensCan J Physiol Pharmacol, 2006; 84: 1021-1028.Nuclear medicine imaging in veterinary oncology Peremans K, Van Bree P, Audenaert K, Van de Wiele CTijdschrift voor Diergeneeskunde, 2006Early prediction of the efficacy of endocrine therapy in advanced breast cancer patients using 99mTc-Depreotide scintigraphy Vanden Bossche B, Van Belle S, De Winter F, Signore A, Van de Wiele CJ Nucl Med, 2006, 47: 6-13Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis Coppieters K, Dreier T, Silence K, Haard HD, Lauwereys M, Casteeks P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers PArthritis Rheumatism, 2006: 1856-1866Synthesis of 99mTc-HYNIC-Interleukin-12, a new specific radiopharmaceutical for imaging T-lymphocytes A Annovazzi, C D’Alessandria, E Bonanno, SJ Mather, B Cornelissen, C Van de Wiele, RA Dierckx, M Mattei, G Palmieri, F Scopinaro, A SignoreEur J Nucl Med, 2006, 33: 474-482Valine-based biphenylsulfonamide matrix metalloproteinase inhibitors as tumor imaging agents. Oltenfreiter R, Staelens L, Kersemans V, Cornelissen B, Frankene F, Foidart J, Van de Wiele C, Slegers GApplied Radiation and isotopes, 2006, 64: 677-685Imaging probes targeting matrix metalloproteinases Van de Wiele C, Oltenfreiter RCancer Biother Radiopharm, 2006; 21: 409-417Sequential 99mTc-HYNIC Annexin-V imaging for predicting response to therapy S Rotteye, C Lahorte, S Van Belle, C Van de WieleJ Nucl Med, 2006, 47: 1813-1818Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for HCC B Lambert, L De Ridder, F De Vos, G Slegers, V De Gelder, C Van de Wiele, H ThierensCan J Physiol Pharmacol, 2006, 84: 1021-1028Optimized tracer-dependent dosage cards to obtain weight-dependent effective doses F Jacobs, H Ham, C Van de Wiele , R Dierckx , H ThierensEur J Nucl Med, 2005, 32: 581-588.Incremental prognostic value of combined perfusion and function assessment during myocardial gated SPECT in patients aged 75 years or older De Winter O, Velghe A, Van de Veire N, De Bondt P, De Buyzere M, Van de Wiele C, De Backer G, Gillebert TC, Dierckx RA, De Sutter JJ Nucl Cardiol 2005; 12: 662-670.188Re-HDD/lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial B Lambert, K Bacher, L Defreyne, F Gemmel, H Van Vlierberghe, JM Jeong, RA Dierckx, C Van de Wiele, H Thierens, F De Vos FJ Nucl Med, 2005; 46: 60-66.Radiolabelled lipiodol therapy for HCC in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome B Lambert, M Praet, P Van Langenhove, R Troisi, B de Hemptinne, F Gemmel, H Van Vlierberghe, C Van de WieleCancer Biother Radiopharm, 2005; 20: 209-214.Radiopharmaceuticals for treatment of HCC B Lambert, C Van de WieleEur J Nucl Med, 2005; 32: 980-989.188Re-HDD/Lipiodol for Treatment of Hepatocellular Carcinoma: A Feasibility Study in Patients with Advanced Cirrhosis Lambert B, Bacher K, De Keukeleire K, Smeets P, Colle I, Jeong JM, Thierens H, Van de Wiele CJ Nucl Med, 2005; 46: 1326-1332.Small animal imaging by means of conventional planar and pinhole SPECT gamma camera imaging K Peremans, B Cornelissen, B Van den Bossche, K Audenaert, C Van de WieleVet Radiol and Ultrasound, 2005, 46: 162-170A forum for IRIST C Van de Wiele, A SignoreQuarterly Journal of Nuclear medicine, 2005, 49: 299-300Absence of Tc-99m HIG joint uptake in a patient suffering from SLE presenting with polyarticular joint complaints F Jacobs, RA Dierckx, E Vrancken, F De Vos, C Van de WieleClin Nucl Med, 2005, 30: 124-125Differences of cortical 5-HT2a receptor binding with SPECT in subtypes of anorexia nervosa I Goethals, M Vervaet, K Audenaert, F Jacobs, C Van de Wiele, H Ham, RA Dierckx, C Van HeeringenJ Psychiatr Res, 2005, may, epub ahead of printBlunted prefrontal perfusion response in depressed patients using SPECT and the TOL task I Goethals, K Audenaert, F Jacobs, C Van de Wiele, H Pyck, A Vandierendonck, C Van Heeringen, R DierckxPsychiatry Res, 2005, 139: 31-40Radiolabelled lipiodol therapy for HCC in patients awaiting liver transplantation: pathology of the explant livers and clinical outcome
B Lambert, M Praet, P Van Langenhove, R Troisi, B de Hemptinne, F Gemmel, H Van Vlierberghe,
C Van de WieleCancer Biother Radiopharm, 2005 ; 20: 209-214In vivo apoptosis detection with radioiodinated Annexin V in LoVo tumour bearing mice following Tipifarnib (Zarnestra, R115777) farnesyltransferase inhibitor therapy. B Cornelissen, C Lahorte, V Kersemans, G Capriotti, E Bonano, A Signore, C Van de Wiele, R Dierckx, G Slegers.Nucl Med Biol, 2005, 32: 233-239In vivo evaluation of [(123)I]-3-(4-iodobenzyl)-1,2,3,4-tetrahydro-8-hydroxychromeno[3,4-c]pyridin-5-one: a presumed dopamine D(4) receptor ligand for SPECT studies. Staelens L, Oltenfreiter R, Blanckaert P, Kersemans V, Vandenbulcke K, Van De Wiele C, Slegers G.Nucl Med Biol, 2005;32:293-299.Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor Cornelissen B, Kersemans V, Burvenich I, Oltenfreiter R, Vanderheyden JL, Boerman O, Van de Wiele C, Slegers GNucl Med Commun, 2005; 26: 147-153.Tryptophane-based biphenylsulphonamide matrix metalloproteinase inhibitors as tumour imaging agents Oltenfreiter R, Staelens L, Vervoort L, Kersemans V, Frankenne F, Noël A, Van de Wiele C, Slegers GCancer Biother Radiopharm, 2005; 20: 659-641In Reply to: Use of radiolabeled bombesin in humans (Scopinaro et al. 2005; 23:3170-3171) B Van den Bossche, C Van de WieleJ Clin Oncol, 2005; 23: 1371.Day-to day variability of global and regional left ventricular functional measurements by 99mTechnetiu tetrofosmin determined by Quantitative Gated SPET in patients with heart failure due to CAD. O De Winter, P De Bondt, C Van De Wiele, G De Backer, Rudi A. Dierckx, J De SutterJ Nucl cardiol, 2004, 11: 47-52.Renal toxicity after internal radionuclide therapy B Lambert, M Cybulla, SM Weiner, C Van de Wiele, H Ham, RA Dierckx, A OtteRad Res, 2004; 161: 607-611.99mTc ciprofloxacin planar and tomographic imaging for the diagnosis of infection in the postoperative spine: experience in 48 patients F De Winter, F Gemmel, K Van Laere, O De Winter, B Poffijn, RA Dierckx, C Van de WieleEur J Nucl Med, 2004; 31: 233-239.Molecular imaging in oncology by means of nuclear medicine: facts or fiction C Van de WieleEur J Nucl Med, 2004; 2: 151-154.Receptor imaging by means of nuclear medicine: current status B Van den Bossche, C Van de WieleJ Clin Oncol, 2004; 22: 3593-3607.Cell death detecting radioligands: current state of the art and future perspectives C Lahorte, JL vanderheyden, N Steinmetz, C Van de Wiele, RA Dierckx, G SlegersEur J Nucl Med, 2004, 31: 887-919.New strategies in polypeptide and antibody synthesis N Mertens, F De Vos, J Leoen, E Van Deynse, A Willems, S Schoonooghe, S De Koker, I Burvenich, D Vlieghe, J Grooten, A Kelly, C Van de WieleCancer Biother Radiopharm, 2004, 1: 99-110The proceedings of the 16th IRIST (International Research Group on Immunoscintigraphy and Immunotherapy) Congress 8-10 May 2003, Capri, Italy A Signore A, C Van de Wiele, M De Jong MCancer Biother Radiopharm, 2004, 1: 55-56Radioiodine recombinant TSH: A novel radiopharmaceutical for thyroid cancer metastases detection F Corsetti, M Chianelli, B Cornelissen, C Van de Wiele, C D’Allessandria, G Slegers, S Mather, U Di Mario, S Filetti, F Scopinaro, A SignoreCancer Biother Radiopharm 2004; 1: 57-64.Radiolabelled annexin-V for monitoring treatment response in oncology C Van de Wiele, H Vermeersch, D Loose, A Signore, RA DierckxCancer Biother Radiopharm, 2004, 2: 205-210.The prefrontal cortex: insights from functional neuroimaging using cognitive activation tasks I Goethals, K Audenaert, C Van de Wiele, RA DierckxEur J Nucl Med, 2004, 3; 408-41699mTc-HYNIC Annexin-V C Van de WieleIDRUGS, 2004, 7; 264-269123I-labelled Interleukin-12, a new radiopharmaceutical for imaging th-1 mediated chronic inflammation: in vitro and animal studies A Annovazzi, B Cornelissen, G Slegers, C D’Alessandria, E Bonanno, C Van de Wiele, F Scopinaro, A SignoreCancer Biother Radiopharm 2004, in pressIntra-, Inter- and day-to-day reproducibility of quantitative 99mTc-HYNIC Annexin imaging in head and neck carcinoma H Vermeersch, H Ham,C Lahorte, Loose D, G Slegers, RA Dierckx, C Van de WieleCancer Biother Radiopharm, 2004, 2: 205-210.99mTc-HYNIC Annexin-V imaging of primary head and neck carcinoma, a comparison with CT H Vermeersch, D Loose, C lahorte, K Mervillie, RA Dierckx, N Steinmetz, JL Vanderheyden, C Cuvelier, G Slegers, C Van de WieleNucl Med Commun, 2004, 3: 259-264Radiolabelling, biodistribution and dosimetry of 123I-Mab 14C5: a new monoclonal antibody for radioimmunodetection of tumor growth and metastasis in vivo C lahorte, Bacher K, Burvenich I, Coene E, Cuvelier C, De Potter C, Thierens H, C Van de Wiele, RA Dierckx, Slegers GJ Nucl Med, 2004, 45: 1065-1073Oestrogen mediated regulation of somatostatin receptor expression in human breast cancer cell lines assessed with 99mTc Depreotide B Van Den Bossche, E D’Haeninck, F De Vos, RA Dierckx, M Bracke, C Van de WieleEur J Nucl Med, 2004, 31: 1022-103099mTc depreotide scan compared with 99mTc MDP bone scintigraphy for the detection of bone metastases and prediction of hormonal treatment response in breast cancer B Van Den Bossche, E D’Haeninck, F De Winter, S Van Belle, RA Dierckx , C Van de WieleNucl Med Commun, 2004, 25: 787-792Relationship between Fas-L expression, MMP-9 expression, microvesseldensity and quantitative 99mTc-HYNIC Annexin imaging in squamous cell carcinoma of the head and neck H Vermeersch, K Mervillie, C Lahorte, D Loose, N Steinmetz, G Slegers, RA Dierckx , C Van de WieleEur J Nucl Med, 2004, 31: 1016-1021The 17th IRIST MEETING REPORT C Van de Wiele, A SignoreCancer Biotherapy and Radiopharmaceuticals, 2004; 19: 719-722Biodistribution and dosimetry of 99mTc Depreotide in patients B Van den Bossche, E D’Haeninck, K Bacher, H Thierens, S Van Belle, R Dierckx, C Van de WieleCancer Biother Radiopharm 2004, 2004; 19: 779-787Comparison of cortical 5-HT2A receptor binding in bulimia patients and healthy volunteers. I Goethals, M Vervaet, K Audenaert, C Van de Wiele, H Ham, M Vandecapelle, G Slegers, C van Heeringen , RA Dierckx.Am J Psychiatry, 2004, 10: 1916-1918Neuroactivation using SPECT and the stroop coloured word test in patients with diffuse brain injury I Goethals, K Audenaert, F Jacobs, E Lannoo, C Van de Wiele, H Ham, A Otte, K Oostra, R DierckxJ Neurotrauma, 2004, 21; 1059-1069Application of a neuropsychological activation probe with SPECT: the tower of London task in healthy volunteers I Goethals, F Jacobs, K Audenaert, C Van de Wiele, P Hanneke, A Vandierendonck, C Van Heeringen, RA DierckxNucl Med Commun , 2004, 2; 177-182.In vitro and in vivo suitability of 123I-hEGF for monitoring farnesyl transferase inhibitor therapy B Cornelissen, T Thonissen, V Kerseman, C Van de Wiele, F Jacobs, RA Dierckx, G SlegersNucl Med Biol, 2004, 31: 379-389Registration accuracy of Gd-153 transmission images of the brain F Jacobs, M Koole, I Goethals, C Van de Wiele, H Ham, Dierckx RAEur J Nucl Med, 2004, 31; 11: 1495-1499Advances and prospects in radioimmunoimaging C Van de Wiele, H Revets, N MertensQuarterly Journal of Nuclear Medicine, 2004, 48: 317-325.The choice of radiopharmaceutical to image breast cancer G Capriotti, C Van de Wiele, F Scopinaro, A SignoreWorld J Nucl Med, 2004; 3: 258-260Validation of planar and tomographic radionuclide ventriculography by a dynamic ventricular phantom P De Bondt, S Vandenberghe, S De Mey, P Segers, O De Winter, J De Sutter, C Van de Wiele, P Verdonck, RA DierckxNucl Med Comun, 2003; (24)7: 771-777.Tomographic radionuclide ventriculography measurements tested with a biventricular dynamic physical phantom P De Bondt, K Nichols, S Vandenberghe, P Segers , O De Winter, J De Sutter, C Van de Wiele, P Verdonck, S Bergmann, RA Dierckx.J Nucl Med, 2003: 44(6): 967-972.Place of ultrasonography in the assessment of renal function in the old old N Van den Noortgate, A Velghe, M Petrovic, C Van de Wiele, N lameire, D Voet, M AfschriftJ Nephrol, 2003; 16: 658-662.FDG PET for the diagnosis of infection in the postoperative spine F De Winter, F Gemmel, C Van de Wiele, B Poffijn, D Uyttendaele, RA DierckxSpine, 2003; 28: 1314-1319.Nuclear medicine imaging to predict response to radiotherapy: past and future C Van de Wiele, C Lahorte,W Oyen, O Boerman, I Goethals, RA DierckxIJROBP, 2003; 1: 5-15.Novel PET and SPECT radiopharmaceuticals for imaging breast tumor biology C Van de Wiele, A Signore, R Waterhouse, RA Dierckx, F ScopinaroNucl Instrum Meth A, 2003; A497: 30-38.Is Flumazenil PET useful for detecting epileptic foci : a review I Goethals, C Van de Wiele, P Boon, RA DierckxEur J Nucl Med, 2003; 30: 325-328.Fluorine-18 2-deoxy-D-glucose positron emission tomography in neoplastic disorders of the gastrointestinal tract A Annovazzi, M Peeters, A Signore, RA Dierckx, C Van de WieleGastroenterology, 2003; 125: 1235-1245.Nuclear Medicine Imaging for the assessment of primary and recurrent head and neck carcinoma using routinely available tracers Vermeersch H, Loose D, Ham H, Otte AS, Van de Wiele CEur J Nucl Med, 2003, 30: 1689-1700False-negative Tc-99m MIBI scintigraphy in a patient with histopathological-proven recurrent high-grade oligodendroglioma I Goethals, O De Winter, A Annovazzi, A Signore, RA Dierckx, C Van de WieleClin Nucl Med, 2003, 28(4): 299-301Biodistribution and dosimetry of 123I-rh-annexin V in mice and humans C Lahorte, C Van de Wiele, K Bacher, B Van den Bossche, H Thierens, G Slegers, RA DierckxNucl Med Commun, 2003, 24: 871-880Non-Invasive quantitative tumour apoptosis imaging by means of 99mTc-HYNIC Annexin single photon emission computerized tomography C Van de Wiele, C Lahorte, H Vermeersch, Loose D, Mervillie C, Cuvelier C, Slegers G, Dierckx RAJ Clin Oncol, 2003, 21: 3483-348799mTc Sestamibi and 99mTc Tetrofosmin scintigraphy to predict resistance to chemotherapy: a critical review C Van de Wiele, S Rottey, I Goethals, J Buscombe, S van Belle, F De Vos, RA DiercxkNucl Med Commun 2003, 24: 945-950The role of nuclear medicine in the prediction and detection of radiation-associated extrathoracic damage I Goethals , RA Dierckx, G De Meerleer, F Gemmel, W De Neve , C Van de WieleNucl Med Commun, 2003, 24: 845-852The exceptional brain of Maurice Ravel A Otte, P De Bondt, C Van de Wiele, K Audenaert, RA DierckxMed Sci Monitor 2003; 9(6): RA113-138Nuclear medicine in the prediction and detection of radiation associated normal tissue damage of kidney, brain, bone marrow and salivary glands. Goethals I, Dierckx R, De Meerleer G, Gemmel F, De Neve W, Van De Wiele C.Nucl Med Commun. 2003 Aug;24(8):845-52.The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage: a review I Goethals, O De Winter, J De Sutter, P De Bondt, RA Dierckx, C Van de WieleAnn Oncol, 2002, 13: 1331-1339.Peptide receptor imaging: Advances in the diagnosis of pulmonary diseases C Van de Wiele, A. Signore, RA DierckxAm J Resp Med; 2002, 1: 177-183.Discordant findings between 99mTc HMPAO mixed white blood cells and 99mTc Leucoscan in a patient suffering from aspergillosis of the lung I Goethals, O De Winter, L D’Ignazio, A Signore, RA Dierckx, C Van de WieleClin Nucl Med, 2002; 27: 596-596.Is there a role for nuclear medicine imaging in routine assessment of infectious brain pathology I Goethals, RA Dierckx, K Van Laere, A Signore, C Van de WieleNucl Med Commun, 2002; 23: 819-826.Nuclear medicine imaging for prediction or early assessment of response to chemotherapy in patients suffering from breast carcinoma C. Van de Wiele, RA. Dierckx, F. Scopinaro, R. Waterhouse, A. Annovazzi, A. Kolindou, A. SignoreBreast Cancer Res Treat, 2002; 72: 275-282.Fluorodeoxyglucose triple headed coincidence detection imaging in oncology : preliminary results and comparison with dedicated PET F De Winter, C Van de Wiele, S Vandenberghe, B Vandenbossche, Y D’Asseler, D Huglo, RA DierckxMed Science Monitor, 2002; 8: MT89-94High-dose 67Ga versus FDG PET for restaging of lymphoma patients B Van Den Bossche, B Lambert, F De Winter, RA Dierckx, L Noens, C Van de WieleNucl Med Commun, 2002; 23: 1079-1083Assessment of cancer associated biomarkers by positron emission tomography: advances and challenges TL Collier, R lecomte, T McCarthy, S Meikle, TJ Ruth, F Scopinaro, A Signore, H VanBrocklin, C Van de Wiele, RN waterhouseDis Markers, 2002; 18: 211-247Tumour angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging C Van de Wiele, R Oltenfreiter, O De Winter, A Signore, G Slegers, RA DierckxEur J Nucl Med, 2002, 29: 699-709Leakage assessment in adjustable laparoscopic gastric banding: radiography versus 99mTc pertechnetate scintigraphy B Vandenbossche, RA Dierckx, G Villeirs, J Pattyn, C Van de WieleEur J Nucl Med, 2002, 29: 1128-1131Brain hypoperfusion in early Alzheimer disease: where to look I Goethals, C Van de Wiele, D Slosman, RA DierckxEur J Nucl Med, 2002, 29: 975-978Biodistribution studies and displacement studies of 123I-5-I-R91150 in the normal dog K Peremans, K Audenaert, F Jacobs, F Dumont, F De Vos, C Van de Wiele, M Vandecapelle, H van Bree F Verschooten, G Slegers, J Mertens, RA Dierckx.Nucl Med Commun, 2002, 23: 1019-1027.Radiolabelled pyrimidines and derivatives for measuring cellular proliferation, an update C Van de Wiele, P De Bondt, M Peeters, RA DierckxNucl Med Commun, 2002, 23: 925-931Toward clinical application of neuropsychological activation probes with SPECT: a spatial working memory task I Goethals, K Audenaert, F Jacobs, C Van de Wiele, C Van Heeringen, RA DierckxJ Nucl Med, 2002,43: 1426-1431The role of whole blood viscosity in premature coronary artery disease in women De Backer TL, De Buyzere M, Segers P, carlier S, De Sutter J, Van de Wiele C, De Backer GAtherosclerosis, 2002, 165(2): 367-373Fibrinogen and C-reactive protein on admission as markers of final infarct size after primary angioplasty for acute myocardial infarction J De Sutter, M De Buyzere, P Gheeraert, C Van de Wiele, J Voet, M De Pauw, RA Dierckx, G De Backer, Y TaeymansAtherosclerosis 2001, 157(1): 189-196.Age- and gender-specific differences in left ventricular cardiac function and volumes determined by gated SPECT P De Bondt, C Van de Wiele, J De Sutter, F De Winter, G De Backer, RA DierckxEur J Nucl Med, 2001, 38(5): 620-624.Aseptic loosening of a knee prosthesis as imaged on FDG-PET F De Winter, C Van de Wiele, D De Clercq, D Vogelaers, P De Bondt, RA DierckxClin Nucl Med 2001, 25: 923-923.Dual head coincidence F-18 FDG imaging using 19 mm Nal (Tl) crystals for the diagnosis of chronic orthopedic infections: a feasibility study F De Winter, C Van de Wiele, S Vandenberghe, P De Bondt, D De Clercq, Y D’Asseler, RA DierckxJ Comput Assist Tomo 2001; 25(2): 184-189.F-18 Flurorodeoxyglucose positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections F De Winter, C Van de Wiele, D Vogelaers, K De Smet, R Verdonk, RA DierckxJ Bone Joint Surg Am, 2001; 83: 651-660.Biodistribution and dosimetry of 99mTc-ciprofloxacin, a promising agent for the diagnosis of bacterial infection F De Winter, C Van de Wiele, F Dumont, J Van Durme, K Solanki, K Britton, G Slegers, RA Dierckx, H ThierensEur J Nucl Med, 2001; 28: 570-574.Receptor imaging in breast carcinoma: future prospects C Van de Wiele, S Van Belle, G Slegers, RA DierckxEur J Nucl Med 2001, 28; 675-679.Imaging tumour hypoxia : where are we? C. Van de Wiele, A. Signore, F. Scopinaro, R. Waterhouse, RA. DierckxNucl Med Commun, 2001; 22: 945-947.Peptide radiopharmaceuticals for diagnosis and therapy A Signore, A Annovazzi, M Chianelli, L D’Ignazio, C Van de Wiele, R Waterhouse, F Scopinaro.Eur J Nucl Med, 2001; 28: 1555-1565.Synthesis and in vitro evaluation of 123I-labelled human recombinant annexin V C Lahorte, G Slegers, J Philippé, C Van de Wiele, RA DierckxBiomol Eng 2001, 17: 51-53.Technetium-99m-labelled HL 91 versus CT and biopsy for the visualisation of tumor recurrence of squamous head and neck carcinoma C Van de Wiele, J Versijpt, RA Dierckx, M Moerman, M Lemmerling, Y D’Asseler, H VermeerschNucl Med Com 2001, 22(3): 269-275Is there a role for agonist gastrin releasing peptide receptor radioligands in tumour imaging? C Van de Wiele, F Dumont, S Van Belle, G Slegers, SH Peers, RA DierckxNucl Med Comm 2001, 22(1): 5-15High performance liquid chromatographic determination of (iodine-123)-iodomethyl-N,N-diethyltamoxifen derivative in human plasma F De Vos, C Van de Wiele , M Vandecapelle , G Slegers, RA DierckxNucl Med Biology, 2001, 28(3): 335-338Dopaminergic neurotransmission in psychiatry: should selection of patients be based on DSM or ICD criteria? I Goethals, K Audenaert, K Van Laere, C Van de Wiele, RA DierckxEur J Nucl Med, 2001, 28; 785-788Dopamine receptor imaging in alcohol dependency: should personality traits be taken into account I Goethals, C Van de Wiele, K AudenaertEur J Nucl Med; 2001, 28: 1585-1588Iodine-labelled tamoxifen uptake in primary human breast carcinoma C Van de Wiele, V Cocquyt, R Vandenbroecke, F De Vos, S. Van Belle, G Slegers, RA Dierckx.J Nucl Med, 2001, 42: 1818-1820Biodistribution and dosimetry of 99mTc RP527, a gastrin releasing peptide agonist for the visualisation of GRP-receptor expressing malignancies C Van de Wiele, F Dumont, RA Dierckx, SH Peers, JR Thornback, G Slegers, H ThierensJ Nucl Med; 2001, 42: 1722-1727Cardiac fluorine-18 fluorodeoxyglucose imaging using a dual headed gamma camera with coincidence detection: a clinical pilot study J De Sutter, F De Winter, C Van de Wiele, P De Bondt, Y D’Asseler, RA DierckxEur J Nucl Med 2000; 27: 676-685.Infarct size and recurrences of ventricular arrythmias after defibrillator implantation J De Sutter, R Tavernier, C Van de Wiele, H Kazmierczak, RA Dierckx, L JordaensEur J Nucl Med 2000; 27: 807-815.Automatic quantification of defect size using normal templates: a comparative clinical study of three commercially available algorithms. J De Sutter, C Van de Wiele, Y D’Asseler, P De Bondt, G De Backer, P Rigo, RA DierckxEur J Nucl Med 2000; 27: 1827-1834.Prevalence of potential candidates for biventricular pacing among patients with known coronary artery disease: a prospective registry from a single center J De Sutter, P De Bondt, C Van de Wiele, W Fonteyne, RA Dierckx, D Clement, R TavernierPACE 2000; 23: 1718-1721.55Co-EDTA for renal imaging using positron emission tomography (PET); a feasibility study P Goethals, A Volckaert, C Van de Wiele, RA Dierckx, N LameireNucl Med Biol 2000; 27: 77-81.57Co-EDTA renal imaging in rats C Van de Wiele, P Goethals, A Volkaert, F De Winter, H Thierens, RA DierckxNucl Med Comm 2000; 21: 313-316.99mTc-MDP uptake in herniated stomach tissue C De Sadeleer, C Van de Wiele, F De Winter, P De Bondt, RA DierckxClin Nucl Med 2000; 25: 386-387.The usefulness of HIG-scan for the detection of spinal inflammation in ankylosing spondylitis K De Vlam, C Van de Wiele, H Mielants, RA Dierckx, EM VeysClin Exp Rheumatol 2000; 18: 379-382.Imaging of giant cell arteritis: evidence of splenic involvement using FDG positron emission tomography F De Winter, M Petrovic, C Van de Wiele, D Vogelaers, M Afschrift, RA DierckxClin Nucl Med 2000; 25: 633-634.Radiolabeled estradiol derivates to predict response to hormonal treatment in breast cancer: a review C Van de Wiele, F De Vos, G Slegers, S Van Belle, RA DierckxEur J Nucl Med 2000; 27: 1421-1433.Synthesis and in vitro stability of 123-I-labelled annexin V : a potential agent for SPECT imaging of apoptotic cells C Lahorte, F Dumont, G Slegers, C Van de Wiele, RA Dierckx, J PhilippéJ labelled compd rad 2000; 43: 739-751PACS and multimodality in medical imaging Y D’Asseler, M Koole, K Van Laere, S Vandenberghe, L Bouwens, R Van de Walle, C Van de Wiele, I Lemahieu, RA DierckxTechnology and Health Care 2000; 8: 35-42Reverse redistribution on Thallium-201 SPECT after primary angioplasty: a one year follow-up study J De Sutter, C Van de Wiele, RA Dierckx, P Gheeraert, M De Buyzere, Y TaeymansEur J Nucl Med 1999; 26: 633-636.QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life-threatening ventricular arrhythmias J De Sutter, R Tavernier, C Van de Wiele, J De Backer, J Kazmierczak, G De Backer, RA DierckxHeart 1999; 81: 533-538.The Selvester 32-point QRS-score for evaluation of myocardial infarct size after primary coronary angioplasty J De Sutter , C Van de Wiele, M De Buyzere , Y Taeymans , RA Dierckx, G De Backer, DL ClementAm J Cardiol 1999; 83: 255-257.Predictive value of Tc-99m DTPA captopril scintigraphy in patients with a solitary kidney and reduced kidney function. C. Van de Wiele, B Brans, R Vanholder, H Hoeben, K Van Laere, RA DierckxNucl Med Comm; 1999; 20: 263-266.Urinary excretion of tubular proteins, albumin, n-aceyl--D-glucosaminidase and the Tc-99m DMSA absolute renal uptake in partial ureteral obstruction in rats: a functional evaluation of hydronephrotic kidneys K Everaert, C Van de Wiele, J Delanghe, H Vander Eecken, JP Van Haelst, J Ouyand, J Van de Voorde, RA Dierckx, W OosterlinckUrol Res1999; 27 (2): 127-131.Absolute 24h DMSA quantification in patients with severely reduced kidney function: a comparison with 51Cr-EDTA clearance. C Van de Wiele, A Van den Eeckhaut, W Verweire, JP Van Haelst, J Versypt, RA DierckxNucl Med Comm 1999; 20: 829-832.Estimation of risk based on biological dosimetry for patients treated with radioiodine M Monsieurs, HM Thierens, C Van de Wiele, AM Vral, IA Meirlaen, HA De Winter, CJ De Sadeleer, LI De Ridder, JM Kaufman, RA DierckxNucl Med Comm 1999; 20: 911-917.Adaptive response in patients treated with 131I MA Monsieurs, HM Thierens, AM Vral, C Van de Wiele, LI De Ridder, RA DierckxJ Nucl Med 1999; 41: 17-22.Visualisation of the stomach on Re-186 HEDP imaging after therapy for metastasized prostate carcinoma. F De Winter, B Brans, C Van de Wiele, RA DierckxClin Nucl Med 1999; 24: 898-899.Variability study of a non-invasive approach to absolute quantification of cerebral blood flow with 99m-Tc-ECD using the aortic activity as arterial input estimate. K Van Laere, C Van de Wiele, Y Van Belle, K Audenaert, RA DierckxNucl Med Comm 1999, 20: 33-4099mTc-sestamibi imaging in pediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein B De Moerloose, C Van de Wiele, C Dhooge, J Philippé, F Speleman, Y Benoit, G Laureys, RA DierckxEur J Nucl Med 1999; 26: 396-403Laparoscopic adjustable silicone gastric banding leakage assessed using 99mTc- Pertechnetate scintigraphy: a report of three cases AC Van den Eeckhaut, G Villeirs, C Van de Wiele, J Versijpt, P Pattyn, RA DierckxJ Nucl Med 1999; 40: 783-785MRI-SPECT and SPECT-SPECT brain co-registration: evaluation of the performance of eight different algorithms M Koole, Y D’Asseler, R Van de Walle, C Van de Wiele, I Lemahieu, RA DierckxNucl Med Comm 1999; 20 : 659-669Biodistribution and dosimetry of (123-iodine)-iodomethyl-N, N diethyltamoxifen: an (anti)oestrogen receptor radioligand C Van de Wiele, F De Vos, J De Sutter, F Dumont, G Slegers, RA Dierckx, H ThierensEur J Nucl Med 1999; 26: 1259-1264Age and gender related 24 hours DMSA uptake in children with normal DMSA scintigrams C Van de Wiele, M Simons, J Van de Walle, J De Sutter, K Everaert, RA DierckxNucl Med Comm 1998; 19: 149-154.Optimizing background correction when calculating differential renal function in the presence of hydroureteronephrosis using 99mTc-DTPA. C Van de Wiele, C De Sadeleer, M Koole, Y D’Asseler, K Everaert and RA DierckxNucl Med Comm, 1998; 19: 251-255.Urinary alpha 1 microglobulin detects uropathy. A prospective study in 483 patients K. Everaert, J Delanghe, C Van de Wiele, P Hoebeke, RA Dierckx, N Lameire, W OosterlinckClin Chem Lab Med, 1998; 36 (5): 309-315.Elevated tubular proteinuria, albuminuria and decreased urinary N-acetyl--D-glucosaminidase activity following unilateral total ureteral obstruction in rats. K Everaert, W Kerckhaert, J Delanghe, N Lameire, W Sturley, C Van de Wiele, RA Dierckx, J van de Voorde and W Oosterlinck.Urol Res 1998, 26: 285-289.The combined use of urinary -1-microglobuline and Tc-99m DMSA scintigraphy limits irradiation and costs in the diagnosis and follow-up of acute pyelonefritis and cystitis in children K Everaert, A Raes, P Hoebeke, W Samijn, J Delanghe, C Van de Wiele, J Van de WalleEur Urol 1998, 475: 1-5.Synthesis of 123I iodoaminogluthetimide, a possible radioligand for the visualisation of the aromatase enzyme in breast carcinoma by SPECT F De Vos, C Van de Wiele, G Slegers and RA DierckxJ labelled compd rad 1998; XL: 375-376Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo. B Brans, G Laureys, V Schelfhout, C Van de Wiele, CR De Potter, C Dhooge, M Simons, RA DierckxEur J Nucl Med 1998; 25: 144-149A SPECT study to compare Cobalt-57 and Technetium-99m-HMPAO-labeled leukocytes for visualisation of ischemic infarcts. H Stevens, C Van de Wiele, P Santens, HML Jansen, J De Reuck, RA Dierckx, J Korf.J Nucl Med 1998; 39: 495-498Cobalt-57 as a SPECT-tracer in the visualisation of ischemic brain damage in patients with middle cerebral artery stroke H Stevens, S Knollema, DA Piers, C Van de Wiele, HML Jansen, AEJ De Jager, J De Reuck, RA Dierckx, J KorfNucl Med Comm 1998; 19: 573-580Differential renal function measured by Tc-99m DTPA and Tc-99m DMSA in a complete unilateral renal obstruction rat model C Van De Wiele, K Everaert, H Van der Eecken, JP Van Haelst, M Simons, RA DierckxNucl Med Comm 1997; 18: 1036-1039.Aseptic necrosis : a scintigraphic imitator of osseous involvement in Ga-67 avid lymphoma C Van De Wiele, RA Dierckx, L Noens, M SimonsClin Nucl Med 1997; 22: 101-103.Delayed epiphyseal closure attributable to androgen deficiency C Van de Wiele, K Osmanagaoglu, K Audenaert, RA DierckxClin Nucl Med 1997; 22: 567-568.Decreased chemotaxis of lymphocytes labelled withTc-99m HMPAO is possibly related to apoptosis C Van de Wiele, J Philippé, JP Van Haelst, J Van Damme, H Thierens, GE Leroux-Roels, RA DierckxJ Nucl Med 1997; 38: 1417-1421.Comparison of bone scintigraphy, clinical findings and X-rays of the hands at the time of diagnosis in patients suffering from systemic lupus erythematosus and rheumatoid arthritis C Van De Wiele, F Van den Bosch, H Mielants, M Simons, E Veys, RA DierckxJ Rheumatol 1997; 97: 1916-1921.Thallium-201 scintigraphy does not allow visualisation of the thyroid in euthyroid and hyperthyroid patients treated with amiodarone C Van de Wiele, K Osmanagaoglu, M Monsieurs, K Van Laere, JM Kaufman, RA DierckxNucl Med Comm 1997; 18 : 513-516Whole-body bone scan findings in X-linked hypophosphatemia C Van de Wiele, RA Dierckx, L Weynants, M Simons, JM KaufmanClin Nucl Med 1996; 21: 483.Gallium-67 and Technetium-99m-MDP scintigraphy for the detection and follow-up of osseous involvement in Ga-67 avid lymphoma C Van de Wiele, RA Dierckx, M Simons, L NoensJ Nucl Med 1996, 37-13 : 548Does leucocyte scintigraphy answer the need for a more widely available radiopharmaceutical that can detect and assess the proliferative state of lymphoma ? C Van de Wiele, M Simons, L Noens, RA DierckxEur J Nucl Med 1996; 23 : 471-473Lymphocyte labelling with Tc-99m HMPAO : a radiotoxicity study using the micronucleus assay HMA Thierens, AM Vral, JP Van Haelst, C Van de Wiele, KHG Schelstraete, LF De RidderJ Nucl Med 1992; 33: 1167-1174.
Autres publications
Filtres :
publications dans les journaux sans facteurs d'impact
Verhoogde opname vanTc-99m MDP in inwendige organen als enige uiting van diffuse botmetastasering bij borstkanker C Van de Wiele, V Cocquyt, M Simons, S Van Belle, RA DierckxTijdschr Nucl Geneeskd 1996; 18 : 42-43Nuclear Medicine and artificial organs Walgraeve N, Vanholder R, Lambrecht L, Van de Wiele C, Lemahieu I, Dierckx RCourse Book Biomedical Angineering aspects of artificial organs 1996; 1-3 (IBITEC) IBITEC, Ghent, BelgiumAcute rugpijn bij bejaarden : bijdrage van het isotopenonderzoek B Brans, M Simons, C Van De Wiele, J Kuyvenhoven, RA DierckxTijdschrift voor Geneeskunde 1997; 53 1422-1426Evaluatie van de nauwkeurigheid en rekensnelheid van zes algorithmes voor ECD SPECT-SPECT coregistratie M Koole, Y D’Asseler, K Van Laere, C Van de Wiele, RA Dierckx, Lemahieu ITijdschrift Nucl Geneesk 1997; 19: 115-119Cytogenetische studies bij patiënten behandeld met 131I-Nal voor schildklier- aandoeningen of 131I-MIBG voor neuroblastoma. M Monsieurs, H Thierens, A Vral, C Van de Wiele, L De Ridder, RA DierckxTijdschr Nucl Geneeskd 1999; 21 (2): 53-58Sterk verhoogde opname van 99mTc-HMPAO-leukocyten in de longen bij een patiënte met polycystische ziekte van de lever en de nieren F De Winter, C Van de Wiele, J Versijpt, P De Bondt, R Vanholder, RA DierckxTijdschr Nucl Geneeskd 1999; 21 (4): 166-167Verhoogde uteriene FDG-opname tijdens het puerperium P De Bondt, F De Winter, C Van de Wiele, B Brans, Y D’Asseler, RA DierckxTijdschr Nucl Geneeskd 1999; 21 (3): 131The clinical value of nuclear medicine in the assessment of radio- and chemotherapy related pulmonary and cardiac normal tissue damage in patients with breast cancer Goethals I, De Sutter J, De Winter O, Dierckx RA, Van de Wiele CIn: Progress in Breast Cancer Research Nova Science Publishers, Hauppage, NY, USAThe clinical value of nuclear medicine in the assessment of radio- and chemotherapy related pulmonary and cardiac normal tissue damage in patients with Hodgkin’s disease.
Goethals I, Van den Bossche B, Dierckx RA, Van de Wiele CIn: Progress in Lymphoma Research
Nova Science Publishers, Hauppage, NY, USAMolecular aspects of G-protein coupled receptor signalling of relevance for nuclear medicine imaging in psychiatry C Van de Wiele, I Goethals, K Audenaert, A Otte, N MertensIn: Nuclear Medicine in Psychiatry Eds: K Audenaert, C Van Heeringen, A Otte, RA Dierckx Springer verlag, Heidelberg, GermanyPeptide Radiopharmaceuticals for radioguided surgery Signore A, Van de Wiele C, Scopinaro F, Dierckx RAIn: Radioguided surgery Eds: Mariani G, Mariani P, Strauss W. Springer-Verlag, 2008Geïnduceerde zelfdoding van kankercellen C Vangestel, C Van de Wiele, N Van Damme, M PeetersNederlands tijdschrift Oncologie 2011.
publications dans les livres
Functional neuroimaging and chronic fatigue syndrome K Audenaert, L Lambrecht, C Van de Wiele, K Osmanagaoglu, PP De Deyn and RA DierckxIn : SPECT in clinical neurology and psychiatry. Eds : PP De Deyn, RA Dierckx, A Alavi, BA Pickut. John Libbey, London 1997; Chapter 52 : 433-446Synthesis and evaluation of I-123 iodoaminogluthetimide, a ligand for visualization of the aromatase enzyme by SPECT F Devos, C Van de Wiele, G Slegers, RA DierckxIn : Badgastein Conference Proceedings, Textbook volume 23 Austria in radioactive isotopes in Clinical Medicine and Research XXIII, Berghmann H, Köhn H, Sinzinger H. Ed., p99-104, Birkhauser Verlag, Berlin 1999Bone scintigraphy of the hands in early stage lupus erythematosus and rheumatoid arthritis C Van De Wiele, F Van den Bosch, H Mielants, M Simons, E Veys, RA DierckxIn : Year Book of Nuclear Medicine 1999; p 109-111 Eds: A Gottschalk, MD Blaufox, RE Coleman, H Strauss, IG Zubal, PB Hoffer Mosby-Year Book, Inc ISBN 0-8151-3822-9Bone scintigraphy of the hands in early stage lupus erythematosus and rheumatoid arthritis C Van De Wiele, F Van den Bosch, H Mielants, M Simons, E Veys, RA DierckxIn : Year Book of Nuclear Medicine 1999; p 109-111 Eds: A Gottschalk, MD Blaufox, RE Coleman, H Strauss, IG Zubal, PB Hoffer Mosby-Year Book, Inc ISBN 0-8151-3822-9Novel Approaches to receptor imaging in breast carcinoma: methodological and preliminary clinical evaluations C van de Wiele2001; ISBN 90-805957-2-1Fluorodeoxyglucose positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections F De Winter, C Van de Wiele, D Vogelaers, K De Smet, R Verdonk, RA DierckxYear book of Nuclear Medicine 2002 Mosby-Year Book, Inc. ISBNOn the role of nuclear medicine imaging for routine assessment of infectious brain pathology: a questionnaire C Van de Wiele, I Goethals, RA DierckxIn: Nuclear Medicine in the management of inflammatory and infectious disease 2003; 175-185 Eds: A Signore, M Liberatore, F Scopinaro Springer Verlag, Heidelberg, GermanyPositron Emission Tomography Imaging of Clinical Infectious Diseases Van de Wiele C, De Winter O, Ham H, Dierckx RAIn: Methods in Microbiology Eds: Savidge T, Pothoulakis C Elsevier Press, 2005SPECT and PET in IMRT: future prospects Van de Wiele CIn: Image guided IMRT Eds: Bortfeld T, Schmidt-Ullrich R, De Neve W, Wazer DE Springer-Verlag, 2006Nuclear Medicine Imaging for infection of the spine Van de Wiele CIn: Interventional Spine Eds: Slipman C, Derby R, Simeone F, Magu T. Elsevier Press, 2008Scintigrafie bij diabetes voet Van de Wiele CIn: Diabetische voet, management in gespecialiseerde centra Eds: Van Acker K, Bandeleene R, Vermassen F, Leewerijs T Acco Press, 2008Urothelial cell carcinoma in lower urinary tract: radionuclide imaging H Ham, Van de Wiele CIn : Imaging in oncological urology Eds: de la Rosette J, Manyak M, Mukerl G, Harisibhani G, Wijkstra H Springer Verlag, 2009Clinical PET Technology (p.261-286) D’Asseler Y, Van de Wiele CIn : Trends on the use of PET in drug development Eds : Alsinga P, van Waarde A, Paans A, Dierckx R World Scientifc, 2012 ISBN : 9789814464314Nuclear medicine imaging of tuberculosis and HIV Sathekge M, Van de Wiele C, Signore A.2013; 255.271. In: Diagnostic imaging of infectious and inflammatory diseases: a multidisciplinary approach. ISBN: 978-1-118-48441-8Nuclear medicine imaging of infectious and inflammatory disease of the abdomen Martin-Comin J, Casen A, Van de Wiele C.2013; 216-240. In: Diagnostic imaging of infectious and inflammatory diseases: a multidisciplinary approach. ISBN: 978-1-118-48441-8
éditeur de livres
Guest Editor Cancer Biotherapy and Radiopharmaceuticals 2004;19: 173-261“Proceedings of the 16th IRIST Congress 2003”Guest Editor Current Pharmaceutical Design, 2013, issue dedicated to“Nuclear medicine imaging for personalized medicine”, in pressSomatostatin analogues: from research to clinical practice
Eds: Hubalewska-Dydyczyck A, Signore A, Buscombe J, Van de Wiele C, De Jong M, Dierckx RSpringer Verlag, 2015, pp 1-360, ISBN: 978-1-118-52153-3